Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 years
Trial results and drug combinations for bortezomib in multiple myeloma
Tackling unmet needs in lymphoma
What does the TOURMALINE-MM2 study tell us about the use of ixazomib in multiple myeloma?
Which is the best combination therapy in relapsed and refractory multiple myeloma?